CJC-1295 Compound Reference
Published · Last updated · Publisher: ENOS Labs USA
What is CJC-1295?
CJC-1295 is a synthetic analog of the first 29 residues of growth hormone releasing hormone. The original form carries a drug affinity complex that binds albumin to extend its half life, and two 2006 studies in healthy adults measured growth hormone and IGF-1 responses. It never reached approval and is not an FDA approved drug.
- Synonyms
- DAC:GRF; Modified GRF(1-29); CJC-1295 without DAC (Mod GRF 1-29)
- Classification
- Synthetic growth hormone releasing hormone (GHRH) analog
What is CJC-1295?
The name covers two materials. CJC-1295 with DAC includes a reactive linker that attaches to circulating albumin. Material sold as CJC-1295 without DAC is the modified GRF(1-29) sequence alone. The two have different structures and different expected masses.
Research context
Published work examined pharmacokinetics and growth hormone axis responses in early human studies and in endocrine models.
Mechanisms being investigated
- Activation of the GHRH receptor on pituitary somatotrophs, stimulating growth hormone release.
Research status
Approval status: Not approved for human use. Highest evidence tier in the cited literature: preclinical and early human.
Not approved. Clinical development did not continue to approval, and it is not an FDA approved drug.
Established findings
- Its GHRH receptor target.
- Early human pharmacology studies were published in 2006.
Preliminary or experimental findings
- Any long term outcome or safety data, which do not exist from controlled trials.
Chemical reference information
| Molecular formula | C165H269N47O46 |
|---|---|
| Molecular weight | 3647.2 g/mol |
| CAS number | 446262-90-4 |
| PubChem CID | 91971820 |
Values taken from the PubChem record. PubChem record for CJC-1295. Material labeled without DAC has a different structure and mass.
Testing considerations
- Confirm whether the vial is the DAC or non DAC form; the expected mass differs.
- Several substituted residues make sequence confirmation by MS/MS useful.
General methods are explained in purity versus identity testing.
What is still unknown
- Behavior of the non DAC form, which has little published characterization.
Related resources
ENOS catalog listing: CJC-1295 + IPA Blend 10MG
Research use limitations
This page summarizes published research and regulatory status. It is not medical advice and does not describe any use in people. Material supplied by ENOS Labs USA is for in-vitro laboratory research only and is not a drug product, even where a related drug has been approved.
To continue, see recovery and performance research, how to read a certificate of analysis, why purity and identity are separate tests, the compound directory and the peptide testing glossary.
References
Each source below was opened and checked against its PubMed, ClinicalTrials.gov or PubChem record. Links open in a new tab.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (PMID 16352683)The Journal of Clinical Endocrinology & Metabolism, 2006 · PubMed
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog (PMID 17018654)The Journal of Clinical Endocrinology & Metabolism, 2006 · PubMed
- CJC-1295 compound record (PubChem CID 91971820)PubChem · NIH National Library of Medicine
These products are sold strictly for in-vitro laboratory research and are not intended for human consumption, diagnosis, treatment, or any therapeutic use. Purchaser must be 18 years of age or older and confirms they are a qualified researcher.